
NLNK
Other · Other · $33.2M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Mar 31, 2020
EPS trend, 90 days to now · 30-day revisions 0 up, 0 down
Beat estimates in 4 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Feb 28, 2019 | Time not confirmed | -0.34 | -0.28 | +16.5% |
| Nov 1, 2018 | Time not confirmed | -0.40 | -0.20 | +50.3% |
| Aug 1, 2018 | Time not confirmed | -0.60 | -0.47 | +22.4% |
| May 4, 2018 | Time not confirmed | -0.55 | -0.49 | +10.4% |
| Mar 2, 2018 | Time not confirmed | -0.67 | -0.37 | +44.4% |
NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric…